FDA adds warnings on possible heart, diabetes risk with prostate cancer drugs
This article was originally published in Scrip
FDA has issued an alert that says that gonadotropin-releasing hormone (GnRH) agonists primarily used to treat men with prostate cancer mustcarry new warnings about a possible increased risk of certain cardiovascular diseases (heart attack, sudden cardiac death, stroke) and diabetes. The drugs involved include Abbott's Lupron Depot (leuprolide acetate for depot suspension), AstraZeneca's Zoladex (goserelin), Sanofi-Aventis's Eligard (leuprolide acetate), and Watson Pharmaceuticals' Trelstar (triptorelin pamoate). There are also some generic products.